



## **Polymer Factory Sweden AB (publ) carries out directed share issues totaling SEK 2.28 million**

The Board of Directors of Polymer Factory Sweden AB (publ) ("Polymer Factory" or the "Company") today announces that it has resolved on a directed issue of 3,100,666 shares at a subscription price of SEK 0.60 per share. The Board has also resolved, subject to subsequent approval by an Extraordinary General Meeting, on a directed issue of 691,763 shares to Board members and senior executives (the "Issues"). Notice of the Extraordinary General Meeting will be published through a separate press release.

The Issues are carried out for the purpose of strengthening the Company's working capital and meeting increased demand for SpheriCal®, the Company's polymer-based calibrant for mass spectrometry.

The Issues are carried out at a subscription price of SEK 0.60 per share, corresponding to approximately a 5% discount to the average share price during the last ten trading days.

Through the Issues, Polymer Factory will receive total proceeds of approximately SEK 2.28 million.

### **Tranche 1**

The Board of Directors has resolved on a directed issue of 3,100,666 shares, based on the authorization granted by the Annual General Meeting on 3 June 2025. Through this part of the Issue, the Company will receive approximately SEK 1.86 million.

The subscribers in tranche 1 are Axel Lindberg, Capmate AB, Cibet AB, Daniel Nilsson, John Moll, Niclas Löwgren, Niklas Estensson and Jinderman & Partners AB (<http://jinderman.se>).

### **Tranche 2**

The Board of Directors has resolved, subject to approval by an Extraordinary General Meeting, on a directed issue of 691,763 shares. Through this part of the Issue, the Company will receive approximately SEK 0.42 million.

The subscribers in tranche 2 are Eva Malmström Jonsson, Leif Gustafsson Gynnerstedt, SCEM Consulting AB (Michael Malkoch) and NordicBlue AB (Mats Wallnér).

The investors in tranche 2 consist of members of the Board of Directors and members of the Company's management, as well as their wholly owned companies. Consequently, approval by the General Meeting must be supported by at least nine-tenths of both the votes cast and the shares represented at the meeting.

**Deviation from shareholders' preferential rights**

The size of the Issue is limited to such an extent that the costs of conducting a rights issue would be disproportionate in relation to the capital raised. Conducting a directed issue allows a larger share of the proceeds to accrue to the Company.

The Board of Directors considers that the subscription price has been determined on market terms through arm's length negotiations with the investors and by comparison with similar transactions.

**Dilution**

Through the Issues, provided that tranche 2 is carried out, the Company's share capital will increase by SEK 379,243, from SEK 1,617,497 to SEK 1,996,740.

The total number of shares is expected to increase by 3,792,429 shares, from 16,174,966 to 19,967,395 shares.

The Issues will result in a dilution effect of approximately 19% for existing shareholders, based on the total number of shares and votes in the Company after completion of the Issues.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-02-2026 09:23 CET.

**For more information, please contact:**

Mats Wallner, CEO

Phone: +46 (0) 70 951 95 06

E-mail: [mats.wallner@polymerfactory.com](mailto:mats.wallner@polymerfactory.com)

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at [www.polymerfactory.com](http://www.polymerfactory.com).